Cancers of unknown primary origin: current perspectives and future therapeutic strategies

Giulia Maria Stella, Rebecca Senetta, Adele Cassenti, Margherita Ronco, Paola Cassoni, Giulia Maria Stella, Rebecca Senetta, Adele Cassenti, Margherita Ronco, Paola Cassoni

Abstract

It is widely accepted that systemic neoplastic spread is a late event in tumour progression. However, sometimes, rapidly invasive cancers are diagnosed because of appearance of metastatic lesions in absence of a clearly detectable primary mass. This kind of disease is referred to as cancer of unknown primary (CUP) origin and accounts for 3-5% of all cancer diagnosis. There is poor consensus on the extent of diagnostic and pathologic evaluations required for these enigmatic cases which still lack effective treatment. Although technology to predict the primary tumour site of origin is improving rapidly, the key issue is concerning the biology which drives early occult metastatic spreading. This review provides the state of the art about clinical and therapeutic management of this malignant syndrome; main interest is addressed to the most recent improvements in CUP molecular biology and pathology, which will lead to successful tailored therapeutic options.

Figures

Figure 1
Figure 1
Tacking the primary: from multiple malignant nodules to CUPs.
Figure 2
Figure 2
Diagnostic algorithm to characterize metastatic adenocarcinoma from unknown primary. (CK: cytokeratin; TTF1: thyroid transcription factor 1; ER: estrogen receptor; CA125: cancer antigen 125; tireo: tireoglobulin; VIM: vimentin; PSA: prostate specific antigen)

References

    1. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. On behalf of the ESMO guidelines working group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(suppl 6):vi64–vi68.
    1. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12(8):1272–1280.
    1. Pavilidis N, Fizazi K. Carcinoma of unknown primary (CUP) Crit Rev Oncol Hematol. 2009;69:271–278. doi: 10.1016/j.critrevonc.2008.09.005.
    1. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumors: a literature review. Annals of Oncology. 2003;14(2):191–96. doi: 10.1093/annonc/mdg068.
    1. Holmes FF, Fouts TL. Metastatic cancer of unknown primary site. Cancer. 1970;26(4):816–820. doi: 10.1002/1097-0142(197010)26:4<816::AID-CNCR2820260413>;2-R.
    1. Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist. 1997;2(3):142–152.
    1. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005. doi: 10.1016/S0959-8049(03)00547-1.
    1. Shu X, Liu H, Ji J, Sundquist K, Försti A, Sundquist J, Hemminki K. Subsequent cancers in patients diagnosed with cancer of unknown primary (CUP): etiological insights? Ann Oncol. 2011. in press .
    1. Hainsworth JD, Gereco FA. Treatment of patients with cancer of unknown primary site. N Engl J Med. 1993;329(4):257–263. doi: 10.1056/NEJM199307223290407.
    1. Mierke CT. Cancer cells regulate biomechanical properties of human microvascular endothelial cells. J Biol Chem. 2011;286:40025–40037. doi: 10.1074/jbc.M111.256172.
    1. Ecles SA, Welch DR. Metastases: recent discoveries and novel treatment strategies. Lancet. 2007;307(9574):1742–1757.
    1. Marchesi F, Locatelli M, Solinas G, Erreni M, Allavena P, Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol. 2010;224(1-2):39–44. doi: 10.1016/j.jneuroim.2010.05.007.
    1. Rowe RG, Weiss SJ. Breaching the basement membrane: who, when and how? Trends Cell Biol. 2008;18(11):560–574. doi: 10.1016/j.tcb.2008.08.007.
    1. Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2011. in press .
    1. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA. Markers of adenocarcinoma characteristic of the site of origin: development of diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766–3772. doi: 10.1158/1078-0432.CCR-04-2236.
    1. Rossi G, Nannini N, Costantini M. Morphology and more specific immunohistochemical stains are fundamental prerequisites in detection of unknown primary cancer. J Clin Oncol. 2009;27(4):649–650.
    1. De Jong D, Horlings H, Wesseling J, van't Veer L. In reply to Rossi G et al. J Clin Oncol. 2009;27(4):651–652.
    1. Horlings HM, van Laar R, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D. Gene expression profiling to identify the histogenic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008;26(27):4435–4441. doi: 10.1200/JCO.2007.14.6969.
    1. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 2008;9(6):596–10. doi: 10.1016/S1470-2045(08)70151-7.
    1. Greco FA, Hainsworth JD. In: Cancer: Principles and Practice of Oncology. 9. DeVita TV, Hellman S, Rosenberg SA, editor. Philadelphia: Wolters, Kluwer/Lippincott, Williams and Wilkins; 2011. Cancer of unknown primary; pp. 2033–2051.
    1. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol. 2007;46(5):592–601. doi: 10.1080/02841860701243095.
    1. Boellaard R, Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181–200. doi: 10.1007/s00259-009-1297-4.
    1. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238(2):405–422. doi: 10.1148/radiol.2382041977.
    1. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and metaanalysis. Eur Radiol. 2009;19(3):731–744. doi: 10.1007/s00330-008-1194-4.
    1. Werner MK, Pfannenberg C, Öksüz MÖ. Nonspecific FDG uptake in the tongue mimicking the primary tumor in a patient with cancer of unknown primary. Clin Imaging. 2011;35(5):405–407. doi: 10.1016/j.clinimag.2010.09.005.
    1. Dandekar MR, Kannan S, Rangarajan V, Purandare NC, Chaukar DA, Deshmukh A, D'cruz AK. Utility of PET in unknown primary with cervical metastasis: a retrospective study. Indian J Cancer. 2011;48(2):181–186. doi: 10.4103/0019-509X.82882.
    1. Tos T, Klyver H, Drzewiecki KT. Extensive screening for primary tumor is redundant in melanoma of unknown primary. J Surg Oncol. 2011. in press .
    1. Deron PB, Bonte KM, Vermeersch HF, Van de Wiele C. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: impact of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Biother Radiopharm. 2011;6(3):331–4.
    1. Rudmik L, Lau HY, Matthews TW, Bosch JD, Kloiber R, Molnar CP, Dort JC. Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: A prospective clinical trial. Head Neck. 2011;33(7):935–940. doi: 10.1002/hed.21566.
    1. Hu M, Zhao W, Zhang PL, Ju GF, Fu Z, Zhang GL, Kong L, Yang YQ, Ma YD, Yu JM. Clinical applications of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary. Chin Med J (Engl) 2011;124(7):1010–14.
    1. Park JS, Yim JJ, Kang WJ, Chung JK, Yoo CG, Kim YW, Han SK, Shim YS, Lee SM. Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes. 2011;4:56. doi: 10.1186/1756-0500-4-56.
    1. Pak K, Kim SJ, Kim IJ, Nam HY, Kim BS, Kim K, Kim YK. Clinical implication of (18)F-FDG PET/CT in carcinoma of unknown primary. Neoplasma. 2011;58(2):135–139. doi: 10.4149/neo_2011_02_135.
    1. Keller F, Psychogios G, Linke R, Lell M, Kuwert T, Iro H, Zenk J. Carcinoma of unknown primary in the head and neck: Comparison between positron emission tomography (PET) and PET/CT. Head Neck. 2010. in press .
    1. Yabuki K, Tsukuda M, Horiuchi C, Taguchi T, Nishimura G. Role of 18 F-FDG PET in detecting primary site in the patient with primary unknown carcinoma. Eur Arch Otorhinolaryngol. 2010;267(11):1785–1792. doi: 10.1007/s00405-010-1371-3.
    1. Salem S, Patel NH, Barwick T, Al-Nahhas A, Howard DJ, Zerizer I, Win Z. Occult squamous cell carcinoma of the uvula detected by F-18 FDG PET/CT in a case of carcinoma of unknown primary in the head and neck. Clin Nucl Med. 2010;35(10):800–801. doi: 10.1097/RLU.0b013e3181ef09cb.
    1. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37(1):67–77. doi: 10.1007/s00259-009-1205-y.
    1. Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol. 2009;45(3):218–224. doi: 10.1016/j.oraloncology.2008.05.010.
    1. Cianchetti M, Mancuso AA, Amdur RJ, Werning JW, Kirwan J, Morris CG, Mendenhall WM. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope. 2009;119(12):2348–2354. doi: 10.1002/lary.20638.
    1. Padovani D, Aimoni C, Zucchetta P, Paluzzi A, Pastore A. 18-FDG PET in the diagnosis of laterocervical metastases from occult carcinoma. Eur Arch Otorhinolaryngol. 2009;266(2):267–271. doi: 10.1007/s00405-008-0733-6.
    1. Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B, Gumus M, Uner A, Yamac D, Ucgul E, Buyukberber S. Whole body 18 F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev. 2008;9(4):683–636.
    1. Hu M, Li MH, Kong L, Liu NB, Yang GR, Yu JM. (18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin. Zhonghua Zhong Liu Za Zhi. 2008;30(9):699–701.
    1. Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX, Liu ZF. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Nucl Med Commun. 2008;29(9):791–802.
    1. Johansen J, Buus S, Loft A, Keiding S, Overgaard M, Hansen HS, Grau C, Bundgaard T, Kirkegaard J, Overgaard J. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck. 2008;30(4):471–478. doi: 10.1002/hed.20734.
    1. Nassenstein K, Veit-Haibach P, Stergar H, Gutzeit A, Freudenberg L, Kuehl H, Fischer M, Barkhausen J, Bockisch A, Antoch G. Cervical Lymph Node Metastases of Unknown Origin: Primary Tumor Detection with Whole-Body Positron Emission Tomography/Computed Tomography. Acta Radiol. 2007;23:1–8.
    1. Garin E, Prigent-Lejeune F, Lesimple T, Barge ML, Rousseau C, Devillers A, Bouriel C, Habiba MT, Bernard AM, Bridji B, Resche I. Impact of PET-FDG in the diagnosis and therapeutic care of patients presenting with metastases of unknown primary. Cancer Invest. 2007;25(4):232–239. doi: 10.1080/07357900701206331.
    1. Paul SA, Stoeckli SJ, von Schulthess GK, Goerres GW. FDG PET and PET/CT for the detection of the primary tumour in patients with cervical non-squamous cell carcinoma metastasis of an unknown primary. Eur Arch Otorhinolaryngol. 2007;264(2):189–195.
    1. Ambrosini V, Nanni C, Rubello D, Moretti A, Battista G, Castellucci P, Farsad M, Rampin L, Fiorentini G, Franchi R, Canini R, Fanti S. 18 F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med. 2006;111(8):1146–1155. doi: 10.1007/s11547-006-0112-6.
    1. Talantov D, Baden J, Jatkoe T, Hahn K, Yu J, Rajpurohit Y, Jiang Y, Choi C, Ross JS, Atkins D, Wang Y, Mazumder A. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn. 2006;8(3):320–329. doi: 10.2353/jmoldx.2006.050136.
    1. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008;26(27):4442–4448. doi: 10.1200/JCO.2007.14.4378.
    1. Ma XJ, Patel R, Wang X, Salunga R, Murage J, Desai R, Tuggle JT, Wang W, Chu S, Stecker K, Raja R, Robin H, Moore M, Baunoch D, Sgroi D, Erlander M. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130(4):465–473.
    1. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005;65(10):4031–4040. doi: 10.1158/0008-5472.CAN-04-3617.
    1. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, Benjamin H, Shabes N, Tabak S, Levy A, Lebanony D, Goren Y, Silberschein E, Targan N, Ben-Ari A, Gilad S, Sion-Vardy N, Tobar A, Feinmesser M, Kharenko O, Nativ O, Nass D, Perelman M, Yosepovich A, Shalmon B, Polak-Charcon S, Fridman E, Avniel A, Bentwich I, Bentwich Z, Cohen D, Chajut A, Barshack I. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4):462–469. doi: 10.1038/nbt1392.
    1. Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011;17(12):4063–4070. doi: 10.1158/1078-0432.CCR-10-2599.
    1. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafà R, Magri E, Lunardi M, Munerato G, Querzoli G, Maestri I, Ulazzi L, Nenci I, Croce CM, Lanza G, Querzoli P, Negrini M. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol. 2011;225(1):43–53. doi: 10.1002/path.2915.
    1. Stancel GA, Coffey D, Alvarez K, Halks-Miller M, Lal A, Mody D, Koen T, Fairley T, Monzon FA. Identification of tissue of origin in body fluid specimens using a gene expression microarray assay. Cancer Cytopathol. 2011. in press .
    1. Aizenberg MR, Fox BD, Suki D, McCutcheon IE, Rao G, Rhines LD. Surgical management of unknown primary tumors metastatic to the spine. J Neurosurg Spine. 2011. in press .
    1. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K. French Study Group on Carcinomas of Unknown Primary Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20(24):4679–4683. doi: 10.1200/JCO.2002.04.019.
    1. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002;38:409–413. doi: 10.1016/S0959-8049(01)00378-1.
    1. Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol. 2011;8(12):701–710. doi: 10.1038/nrclinonc.2011.158.
    1. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009;35:570–573. doi: 10.1016/j.ctrv.2009.05.005.
    1. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000;18(17):3101–3107.
    1. Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol. 2004;34(11):681–685. doi: 10.1093/jjco/hyh124.
    1. Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N. Hellenic Cooperative Oncology Group. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol. 2008;47(6):1148–1155. doi: 10.1080/02841860701843043.
    1. Greco FA, Burris HA, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20(6):1651–1656. doi: 10.1200/JCO.20.6.1651.
    1. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol. 1997;15(6):2385–2393.
    1. Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, Naot Y, Greco FA. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist. 2009;14(12):1189–9. doi: 10.1634/theoncologist.2009-0112.
    1. Krämer A, Hübner G, Schneeweiss A, Folprecht G, Neben K. Carcinoma of Unknown Primary--an Orphan Disease? Breast Care (Basel) 2008;3(3):164–170.
    1. Møller AK, Pedersen KD, Abildgaard J, Petersen BL, Daugaard G. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol. 2010;49(4):431–435. doi: 10.3109/02841861003649240.
    1. Hainsworth JD, Spigel DR, Burris HA, Shipley D, Farley C, Macias-Perez IM, Barton J, Greco FA. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(10):2448–2454.
    1. Cerezo L, raboso E, Ballestreros AI. Unknown primary cancer of the head and neck: a multidisplinary approach. Clin Transl Oncol. 2011;13(2):88–97. doi: 10.1007/s12094-011-0624-y.
    1. Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, Glisson BS, Chao KS, Schwartz DL, Chronowski GM, El-Naggar AK, Garden AS. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010;78(4):1005–1010. doi: 10.1016/j.ijrobp.2009.09.006.
    1. Shoushtari A, Saylor D, Kerr KL, Sheng K, Thomas C, Jameson M, Reibel J, Shonka D, Levine P. Read P Outcomes of Patients with Head-and-Neck Cancer of Unknown Primary Origin Treated with Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys. 2011. in press .
    1. Colletier PJ, Garden AS, Morrison WH, Goepfert H, Geara F, Ang KK. Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: outcomes and patterns of failure. Head Neck. 1998;20(8):674–681. doi: 10.1002/(SICI)1097-0347(199812)20:8<674::AID-HED3>;2-H.
    1. Hemminki K, Ji J, Sundquist J, Shu X. Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol. 2011;29(4):435–440. doi: 10.1200/JCO.2010.31.5614.
    1. Natoli C, Ramazzotti V, Nappi O, Giacomini P, Palmeri S, Salvatore M, Landriscina M, Zilli M, Natali PG, Tinari N, Iacobelli S. Unknown primary tumors. Biochim Biophys Acta. 2011;1816(1):13–24.
    1. Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol. 1985;21(2):185–189. doi: 10.1016/0277-5379(85)90171-3.
    1. Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N. Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res. 1995;15(6B):2563–2567.
    1. Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer. 2007;97(7):857–861.
    1. Dova L, Pentheroudakis G, Georgiou I, Malamou-Mitsi V, Vartholomatos G, Fountzilas G, Kolaitis N, Kitsiou E, Pavlidis N. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? Clin Exp Metastasis. 2007;24(2):79–86. doi: 10.1007/s10585-007-9055-0.
    1. Bar-Eli M, Abbruzzese JL, Lee-Jackson, Frost P. p53 gene mutation spectrum in human unknown primary tumors. Anticancer Res. 1993;13(5A):1619–1623.
    1. Koo JS, Kim H. Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary. Tumour Biol. 2011;32(5):893–904. doi: 10.1007/s13277-011-0190-5.
    1. Trusolino L, Comoglio PM. Scatter factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer. 2002;2(4):289–300. doi: 10.1038/nrc779.
    1. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006;6(8):637–645. doi: 10.1038/nrc1912.
    1. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3(4):347–361. doi: 10.1016/S1535-6108(03)00085-0.
    1. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011;103(8):645–661. doi: 10.1093/jnci/djr093.
    1. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834–848. doi: 10.1038/nrm3012.
    1. Stella GM, Benvenuti S, Comoglio PM. Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs. 2010;19(11):1381–1394. doi: 10.1517/13543784.2010.522988.
    1. Stella GM, Benvenuti S, Gramaglia D, Scarpa A, Tomezzoli A, Cassoni P, Senetta R, Venesio T, Pozzi E, Bardelli A, Comoglio PM. MET mutations in cancers of unknown primary origin (CUPs) Hum Mutat. 2011;32(1):44–50. doi: 10.1002/humu.21374.
    1. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–827. doi: 10.1038/nature04186.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere